Search

Your search keyword '"Atagi, Shinji"' showing total 533 results
Start Over Author "Atagi, Shinji"
533 results on '"Atagi, Shinji"'

1. Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial

Author

Sakura, Kazuma, Kuroyama, Muneyoshi, Shintani, Yasushi, Funaki, Soichiro, Atagi, Shinji, Kadota, Yoshihisa, Kuribayashi, Kozo, Kijima, Takashi, Nakano, Takashi, Nakajima, Toshihiro, Sasai, Masao, Okumura, Meinoshin, and Kaneda, Yasufumi

Published
2024
Full Text
View/download PDF

2. Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01

Author

Yoshioka, Hiroshige, Ishida, Tadashi, Atagi, Shinji, Tamiya, Akihiro, Nishimura, Takashi, Iwamoto, Yasuo, Kanehara, Masashi, Kim, Young Hak, Korogi, Yohei, Tomii, Keisuke, Katakami, Nobuyuki, Komuta, Kiyoshi, Nishikawa, Masanori, Gemma, Akihiko, Yamaki, Kenichi, Kawahara, Masaaki, Miyakoshi, Chisato, and Mio, Tadashi

Published
2024
Full Text
View/download PDF

8. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion

Author

Tamiya, Motohiro, Tamiya, Akihiro, Suzuki, Hidekazu, Taniguchi, Yoshihiko, Katayama, Kanako, Minomo, Shojiro, Nakao, Keiko, Takeuchi, Naoko, Matsuda, Yoshinobu, Naito, Yujiro, Shiroyama, Takayuki, Okamoto, Norio, Okishio, Kyoichi, Kumagai, Toru, Atagi, Shinji, Imamura, Fumio, and Hirashima, Tomonori

Published
2021
Full Text
View/download PDF

10. Treatment patterns and clinical outcomes of resectable clinical stage III non‐small cell lung cancer in a Japanese real‐world setting: Surgery cohort analysis of the SOLUTION study.

Author

Tsuboi, Masahiro, Murakami, Haruyasu, Harada, Hideyuki, Sobue, Tomotaka, Kato, Tomohiro, Atagi, Shinji, Tokito, Takaaki, Mio, Tadashi, Adachi, Hirofumi, Kozuki, Toshiyuki, Sone, Takashi, Seike, Masahiro, Toyooka, Shinichi, Kitagawa, Hiroshi, Koto, Ryo, Yamazaki, Satoshi, and Horinouchi, Hidehito

Subjects
SURGERY, PATIENTS, THORACOTOMY, RESEARCH funding, SCIENTIFIC observation, TREATMENT effectiveness, CANCER patients, DESCRIPTIVE statistics, ADJUVANT chemotherapy, LONGITUDINAL method, RESEARCH, COMBINED modality therapy, LUNG cancer, TUMOR classification, COMPARATIVE studies, PROGRESSION-free survival, CONFIDENCE intervals, PERIOPERATIVE care, PNEUMONECTOMY, OVERALL survival, PROPORTIONAL hazards models, REGRESSION analysis
Abstract

Background: To elucidate the treatment and surgery outcomes with or without perioperative therapies in Japanese patients with clinical stage III non‐small cell lung cancer (NSCLC) in real‐world settings. Methods: We performed subset analyses of the SOLUTION study, a multicenter, noninterventional, observational study of Japanese patients diagnosed with clinical stage III NSCLC, for those who started first‐line treatment (surgery±perioperative therapy) between January 2013 and December 2014 (study registration: UMIN000031385). Follow‐up data were obtained using medical records from diagnosis to March 1, 2018. Results: Of 149 eligible patients, 67 underwent surgery alone (median age 71 years) and 82 underwent surgery+perioperative therapy (median age 63 years). Lung resection was performed in 137 patients and the others underwent exploratory thoracotomy or other procedures. Perioperative therapies included adjuvant therapy only (n = 41), neoadjuvant therapy only (n = 24), and neoadjuvant+adjuvant therapy (n = 17). The median overall survival (OS) and 3‐year OS rate were 29.3 months and 44.0%, respectively, in patients who underwent surgery alone, and not reached and 61.1%, respectively, in patients who underwent surgery+perioperative therapy. The 3‐year progression‐free survival (PFS) and disease‐free survival (DFS) rates were 42.4% and 47.1%, respectively, in patients who underwent surgery+perioperative therapy and 28.5% and 28.9%, respectively, in patients who underwent surgery alone. In multivariable Cox regression, perioperative therapy was associated with improved OS (hazard ratio [95% confidence interval] 0.49 [0.29–0.81]), PFS (0.62 [0.39–0.96]), and DFS (0.62 [0.39–0.97]) versus surgery alone. Conclusions: Our study suggested that perioperative therapy may be associated with better survival among patients undergoing surgical treatment of clinical stage III NSCLC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Chu, Quincy, Cortot, Alexis, Pujol, Jean-Louis, Moro-Sibilot, Denis, Fabre, Elizabeth, Lamour, Corinne, Bischoff, Helge, Kollmeier, Jens, Reck, Martin, Kimmich, Martin, Engel-Riedel, Walburga, Hammerschmidt, Stefan, Schütte, Wolfgang, Syrigos, Konstantinos, Ho, James Chung Man, Au, Kwok-Hung, Novello, Silvia, Ardizzoni, Andrea, Pasello, Giulia, Gregorc, Vanessa, Del Conte, Alessandro, Galetta, Domenico, Takahashi, Toshiaki, Nakagawa, Kazuhiko, Nishio, Makoto, Yoh, Kiyotaka, Seto, Takashi, Imamura, Fumio, Kumagai, Toru, Hotta, Katsuyuki, Goto, Yasushi, Hosomi, Yukio, Sakai, Hiroshi, Takiguchi, Yuichi, Kim, Young Hak, Kurata, Takayasu, Yamaguchi, Hiroyuki, Daga, Haruko, Okamoto, Isamu, Satouchi, Miyako, Ikeda, Satoshi, Kasahara, Kazuo, Atagi, Shinji, Azuma, Koichi, Aoe, Keisuke, Horio, Yoshitsugu, Yamamoto, Nobuyuki, Tanaka, Hiroshi, Watanabe, Satoshi, Nogami, Naoyuki, Ozaki, Tomohiro, Koyama, Ryo, Hirashima, Tomonori, Kaneda, Hiroyasu, Tomii, Keisuke, Fujita, Yuka, Seike, Masahiro, Nishimura, Naoki, Kato, Terufumi, Ichiki, Masao, Saka, Hideo, Hirano, Katsuya, Nakahara, Yasuharu, Sugawara, Shunichi, Park, Keunchil, Kim, Sang-We, Min, Young Joo, Lee, Hyun Woo, Kang, Jin-Hyoung, An, Ho Jung, Lee, Ki Hyeong, Kim, Jin-Soo, Lee, Gyeong-Won, Lee, Sung Yong, Alexandru, Aurelia, Udrea, Anghel Adrian, Juan-Vidal, Óscar, Nadal-Alforja, Ernest, Gil-Bazo, Ignacio, Ponce-Aix, Santiago, Paz-Ares, Luis, Rubio-Viqueira, Belén, Alonso Garcia, Miriam, Felip Font, Enriqueta, Fuentes Pradera, Jose, Coves Sarto, Juan, Lin, Meng-Chih, Su, Wu-Chou, Hsia, Te-Chun, Chang, Gee-Chen, Wei, Yu-Feng, Chiu, Chao-Hua, Shih, Jin-Yuan, Su, Jian, Cicin, Irfan, Goksel, Tuncay, Harputluoglu, Hakan, Ozyilkan, Ozgur, Henning, Ivo, Popat, Sanjay, Hatcher, Olivia, Mileham, Kathryn, Acoba, Jared, Garon, Edward, Jung, Gabriel, Raj, Moses, Martin, William, Dakhil, Shaker, Garon, Edward B, Ponce Aix, Santiago, Nadal, Ernest, Au, Kwok Hung, Enatsu, Sotaro, Zimmermann, Annamaria, Frimodt-Moller, Bente, and Visseren-Grul, Carla

Published
2019
Full Text
View/download PDF

16. Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.

Author

Morise, Masahiro, Kato, Terufumi, Matsumoto, Shingo, Inoue, Takako, Sakamoto, Tomohiro, Tokito, Takaaki, Atagi, Shinji, Kozuki, Toshiyuki, Takeoka, Hiroaki, Chikamori, Kenichi, Shinagawa, Naofumi, Tanaka, Hiroshi, Horii, Eisuke, Adrian, Svenja, Bruns, Rolf, Johne, Andreas, Paik, Paul K., and Sakai, Hiroshi

Abstract

Tepotinib is a highly selective MET tyrosine kinase inhibitor (TKI) that has demonstrated robust and durable clinical activity in patients with MET exon 14 (METex14) skipping non–small‐cell lung cancer (NSCLC). In the Phase II VISION study, patients received oral tepotinib 500 mg once daily. The primary endpoint was an objective response by an independent review committee (IRC) according to RECIST v1.1 criteria. The secondary endpoints included duration of response (DOR), progression‐free survival (PFS), overall survival (OS), and safety. Here we report the analysis of the efficacy and safety of tepotinib in all Japanese patients with advanced METex14 skipping NSCLC from VISION (n = 38) with >18 months' follow‐up. The median age of the Japanese patients was 73 years (range 63–88), 39.5% of patients were ≥75 years old, 68.4% were male, 55.3% had a history of smoking, 76.3% had adenocarcinoma, and 10.5% of patients had known brain metastases at baseline. Overall, the objective response rate (ORR) was 60.5% (95% confidence interval (CI): 43.4, 76.0) with a median DOR of 18.5 months (95% CI: 8.3, not estimable). ORR in treatment‐naïve patients (n = 18) was 77.8% (95% CI: 52.4, 93.6), and in patients aged ≥75 years (n = 15), ORR was 73.3% (95% CI: 44.9, 92.2). The most common treatment‐related adverse event (AE) with any grade was blood creatinine increase (65.8%), which resolved following tepotinib discontinuation. Other common treatment‐related AEs were peripheral edema (60.5%), hypoalbuminemia (34.2%), diarrhea (28.9%), and nausea (15.8%). In summary, tepotinib demonstrated robust and durable clinical activity irrespective of age or therapy line, with a manageable safety profile in Japanese patients with METex14 skipping NSCLC enrolled in VISION. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Chemoradiotherapy in Elderly Patients With Non–Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301)

Author

Atagi, Shinji, Mizusawa, Junki, Ishikura, Satoshi, Takahashi, Toshiaki, Okamoto, Hiroaki, Tanaka, Hiroshi, Goto, Koichi, Nakagawa, Kazuhiko, Harada, Masao, Takeda, Yuichiro, Nogami, Naoyuki, Fujita, Yuka, Kasai, Takashi, Kishi, Kazuma, Sawa, Toshiyuki, Takeda, Koji, Tomii, Keisuke, Satouchi, Miyako, Seto, Takashi, and Ohe, Yuichiro

Published
2018
Full Text
View/download PDF

20. A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01

Author

Atagi, Shinji, primary, Daimon, Takashi, additional, Okishio, Kyoichi, additional, Komuta, Kiyoshi, additional, Okano, Yoshio, additional, Minato, Koichi, additional, Kim, Young Hak, additional, Usui, Ryo, additional, Tabata, Chiharu, additional, Tamura, Atsuhisa, additional, and Kawahara, Masaaki, additional

Published
2023
Full Text
View/download PDF

21. Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+ non-small-cell lung cancer

Author

Nishio, Makoto, primary, Atagi, Shinji, additional, Goto, Koichi, additional, Hosomi, Yukio, additional, Seto, Takashi, additional, Hida, Toyoaki, additional, Nakagawa, Kazuhiko, additional, Yoshioka, Hiroshige, additional, Nogami, Naoyuki, additional, Maemondo, Makoto, additional, Nagase, Seisuke, additional, Okamoto, Isamu, additional, Yamamoto, Noboru, additional, Igawa, Yuriko, additional, Tajima, Kosei, additional, Fukuoka, Masahiro, additional, Yamamoto, Nobuyuki, additional, and Nishio, Kazuto, additional

Published
2023
Full Text
View/download PDF

24. Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer

Author

Nishio, Makoto, Hida, Toyoaki, Atagi, Shinji, Sakai, Hiroshi, Nakagawa, Kazuhiko, Takahashi, Toshiaki, Nogami, Naoyuki, Saka, Hideo, Takenoyama, Mitsuhiro, Maemondo, Makoto, Ohe, Yuichiro, Nokihara, Hiroshi, Hirashima, Tomonori, Tanaka, Hiroshi, Fujita, Shiro, Takeda, Koji, Goto, Koichi, Satouchi, Miyako, Isobe, Hiroshi, Minato, Koichi, Sumiyoshi, Naoki, and Tamura, Tomohide

Published
2017
Full Text
View/download PDF

25. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

Author

Wang, Rong, Yamada, Tadaaki, Kita, Kenji, Taniguchi, Hirokazu, Arai, Sachiko, Fukuda, Koji, Terashima, Minoru, Ishimura, Akihiko, Nishiyama, Akihiro, Tanimoto, Azusa, Takeuchi, Shinji, Ohtsubo, Koshiro, Yamashita, Kaname, Yamano, Tomoyoshi, Yoshimura, Akihiro, Takayama, Koichi, Kaira, Kyoichi, Taniguchi, Yoshihiko, Atagi, Shinji, Uehara, Hisanori, Hanayama, Rikinari, Matsumoto, Isao, Han, Xujun, Matsumoto, Kunio, Wang, Wei, Suzuki, Takeshi, and Yano, Seiji

Published
2020
Full Text
View/download PDF

28. Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell lung cancer in Japanese patients from CheckMate 816.

Author

Mitsudomi, Tetsuya, Ito, Hiroyuki, Okada, Morihito, Sugawara, Shunichi, Shio, Yutaka, Tomii, Keisuke, Okami, Jiro, Sakakura, Noriaki, Kubota, Kaoru, Takamochi, Kazuya, Atagi, Shinji, Tsuboi, Masahiro, Oizumi, Satoshi, Ikeda, Norihiko, Ohde, Yasuhisa, Ntambwe, Ives, Mahmood, Javed, Cai, Junliang, and Tanaka, Fumihiro

Abstract

In the open‐label, phase III CheckMate 816 study (NCT02998528), neoadjuvant nivolumab plus chemotherapy demonstrated statistically significant improvements in event‐free survival (EFS) and pathological complete response (pCR) versus chemotherapy alone in patients with resectable non‐small‐cell lung cancer (NSCLC). Here we report efficacy and safety outcomes in the Japanese subpopulation. Patients with stage IB–IIIA, resectable NSCLC were randomized 1:1 to nivolumab plus chemotherapy or chemotherapy alone for three cycles before undergoing definitive surgery within 6 weeks of completing neoadjuvant treatment. The primary end‐points (EFS and pCR) and safety were assessed in patients enrolled at 16 centers in Japan. Of the Japanese patients randomized, 93.9% (31/33) in the nivolumab plus chemotherapy arm and 82.9% (29/35) in the chemotherapy arm underwent surgery. At 21.5 months' minimum follow‐up, median EFS was 30.6 months (95% confidence interval [CI], 16.8–not reached [NR]) with nivolumab plus chemotherapy versus 19.6 months (95% CI, 8.5–NR) with chemotherapy; hazard ratio, 0.60 (95% CI, 0.30–1.24). The pCR rate was 30.3% (95% CI, 15.6–48.7) versus 5.7% (95% CI, 0.7–19.2), respectively; odds ratio, 7.17 (95% CI, 1.44–35.85). Grade 3/4 treatment‐related adverse events were reported in 59.4% versus 42.9% of patients, respectively, with no new safety signals identified. Neoadjuvant nivolumab plus chemotherapy resulted in longer EFS and a higher pCR rate versus chemotherapy alone in Japanese patients, consistent with findings in the global population. These data support nivolumab plus chemotherapy as a neoadjuvant treatment option in Japanese patients with resectable NSCLC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Clinical benefit of platinum doublet combination therapy in older adults with advanced non‐small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan

Author

Shimokawa, Mototsugu, primary, Kanazu, Masaki, additional, Saito, Ryusei, additional, Mori, Masahide, additional, Tamura, Atsuhisa, additional, Okano, Yoshio, additional, Fujita, Yuka, additional, Endo, Takeo, additional, Motegi, Mitsuru, additional, Takata, Shohei, additional, Kita, Toshiyuki, additional, Sukoh, Noriaki, additional, Mizuki, Fumitaka, additional, Takenoyama, Mitsuhiro, additional, and Atagi, Shinji, additional

Published
2023
Full Text
View/download PDF

31. Potential of boron neutron capture therapy (BNCT) for malignant peripheral nerve sheath tumors (MPNST)

Author

Fujimoto, Takuya, Andoh, Tooru, Sudo, Tamotsu, Fujita, Ikuo, Fukase, Naomasa, Takeuchi, Tamotsu, Sonobe, Hiroshi, Inoue, Masayoshi, Hirose, Tkanori, Sakuma, Toshiko, Moritake, Hiroshi, Sugimoto, Tohru, Kawamoto, Teruya, Fukumori, Yoshinobu, Yamamoto, Satomi, Atagi, Shinji, Sakurai, Yoshinori, Kurosaka, Masahiro, Ono, Koji, Ichikawa, Hideki, and Suzuki, Minoru

Published
2015
Full Text
View/download PDF

33. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Author

Soria, Jean-Charles, Wu, Yi-Long, Nakagawa, Kazuhiko, Kim, Sang-We, Yang, Jin-Ji, Ahn, Myung-Ju, Wang, Jie, Yang, James Chih-Hsin, Lu, You, Atagi, Shinji, Ponce, Santiago, Lee, Dae Ho, Liu, Yunpeng, Yoh, Kiyotaka, Zhou, Jian-Ying, Shi, Xiaojin, Webster, Alan, Jiang, Haiyi, and Mok, Tony S K

Published
2015
Full Text
View/download PDF

34. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy

Author

Tambo, Yuichi, Hosomi, Yukio, Sakai, Hiroshi, Nogami, Naoyuki, Atagi, Shinji, Sasaki, Yasutsuna, Kato, Terufumi, Takahashi, Toshiaki, Seto, Takashi, Maemondo, Makoto, Nokihara, Hiroshi, Koyama, Ryo, Nakagawa, Kazuhiko, Kawaguchi, Tomoya, Okamura, Yuta, Nakamura, Osamu, Nishio, Makoto, and Tamura, Tomohide

Published
2017
Full Text
View/download PDF

35. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Author

Seto, Takashi, Kato, Terufumi, Nishio, Makoto, Goto, Koichi, Atagi, Shinji, Hosomi, Yukio, Yamamoto, Noboru, Hida, Toyoaki, Maemondo, Makoto, Nakagawa, Kazuhiko, Nagase, Seisuke, Okamoto, Isamu, Yamanaka, Takeharu, Tajima, Kosei, Harada, Ryosuke, Fukuoka, Masahiro, and Yamamoto, Nobuyuki

Published
2014
Full Text
View/download PDF

36. Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non–Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis

Author

Otsubo, Kohei, Kishimoto, Junji, Kenmotsu, Hirotsugu, Minegishi, Yuji, Ichihara, Eiki, Shiraki, Akira, Kato, Terufumi, Atagi, Shinji, Horinouchi, Hidehito, Ando, Masahiko, Kondoh, Yasuhiro, Kusumoto, Masahiko, Ichikado, Kazuya, Yamamoto, Nobuyuki, Nakanishi, Yoichi, and Okamoto, Isamu

Published
2018
Full Text
View/download PDF

37. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study

Author

Takayama, Koichi, Atagi, Shinji, Imamura, Fumio, Tanaka, Hiroshi, Minato, Koichi, Harada, Toshiyuki, Katakami, Nobuyuki, Yokoyama, Takuma, Yoshimori, Kozo, Takiguchi, Yuichi, Hataji, Osamu, Takeda, Yuichiro, Aoe, Keisuke, Kim, Young Hak, Yokota, Soichiro, Tabeta, Hiroshi, Tomii, Keisuke, Ohashi, Yasuo, Eguchi, Kenji, and Watanabe, Koshiro

Published
2016
Full Text
View/download PDF

40. O13-4 Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION)

Author

Morise, Masahiro, primary, Sakai, Hiroshi, additional, Kato, Terufumi, additional, Matsumoto, Shingo, additional, Kumagai, Toru, additional, Sakamoto, Tomohiro, additional, Tokito, Takaaki, additional, Atagi, Shinji, additional, Kozuki, Toshiyuki, additional, Takeoka, Hiroaki, additional, Chikamori, Kenichi, additional, Shinagawa, Naofumi, additional, Tanaka, Hiroshi, additional, Hirashima, Tomonori, additional, Eggleton, S Peter, additional, Bruns, Rolf, additional, Otto, Gordon, additional, and Paik, Paul, additional

Published
2022
Full Text
View/download PDF

43. Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01).

Author

Takeuchi, Susumu, Kubota, Kaoru, Sugawara, Shunichi, Teramukai, Satoshi, Noro, Rintaro, Fujikawa, Kei, Hirose, Takashi, Atagi, Shinji, Minami, Seigo, Iida, Shinichiro, Kuraishi, Hiroshi, Aiba, Tomoiki, Minegishi, Yuji, Matsumoto, Masaru, Seike, Masahiro, Gemma, Akihiko, and Kawahara, Masaaki

Subjects
NON-small-cell lung carcinoma
Abstract

Background: Nab‐paclitaxel (nab‐PTX) has better transfer to tumor tissue than cremophor‐based paclitaxel. It suggests that the optimum dose of nab‐PTX might be lower than the dose and schedule that is widely used. We designed a randomized phase II trial to examine the clinical utility and safety of nab‐PTX in patients with previously treated advanced non‐small cell lung cancer (NSCLC). Methods: Patients were randomly allocated (1:1) to receive nab‐PTX monotherapy at 100 mg/m2 (group A) or 70 mg/m2 (group B). The primary endpoint was progression‐free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and adverse events (AEs). Results: Finally, 81 patients were randomized. Similar results were observed in both groups for PFS (3.75 vs. 3.71 months), OS (13.50 vs. 16.13 months), or ORR (20.5% vs. 23.1%). The incidences of grade 3 or worse AEs were 57.5% in group A and 41.5% in group B. The proportion of serious side effects was 10.0% in group A and 4.9% in group B. Conclusion: Both standard dose and low dose of nab‐PTX monotherapy are active for previously treated NSCLC patients with better safety profile. Therefore, nab‐PTX 70 mg/m2 dose and schedule in the trial would be a reasonable option. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations

Author

Tamiya, Akihiro, Tamiya, Motohiro, Shiroyama, Takayuki, Saijo, Nobuhiko, Nakatani, Takeshi, Minomo, Shojiro, Tsuji, Taisuke, Takeuchi, Naoko, Omachi, Naoki, Kurata, Kanako, Suzuki, Hidekazu., Okamoto, Norio, Okishio, Kyoichi, Hirashima, Tomonori, and Atagi, Shinji

Published
2015
Full Text
View/download PDF

47. A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboringEGFRmutations ( JMTO LC12 ‐01)

Author

Asami, Kazuhiro, primary, Ando, Masahiko, additional, Nishimura, Takashi, additional, Yokoi, Takashi, additional, Tamura, Atsuhisa, additional, Minato, Koichi, additional, Mori, Masahide, additional, Ogushi, Fumitaka, additional, Yamamoto, Akiyoshi, additional, Yoshioka, Hiroshige, additional, Kawahara, Masaaki, additional, and Atagi, Shinji, additional

Published
2022
Full Text
View/download PDF

48. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial

Author

Otsubo, Kohei, primary, Kishimoto, Junji, additional, Ando, Masahiko, additional, Kenmotsu, Hirotsugu, additional, Minegishi, Yuji, additional, Horinouchi, Hidehito, additional, Kato, Terufumi, additional, Ichihara, Eiki, additional, Kondo, Masashi, additional, Atagi, Shinji, additional, Tamiya, Motohiro, additional, Ikeda, Satoshi, additional, Harada, Toshiyuki, additional, Takemoto, Shinnosuke, additional, Hayashi, Hidetoshi, additional, Nakatomi, Keita, additional, Kimura, Yuichiro, additional, Kondoh, Yasuhiro, additional, Kusumoto, Masahiko, additional, Ichikado, Kazuya, additional, Yamamoto, Nobuyuki, additional, Nakagawa, Kazuhiko, additional, Nakanishi, Yoichi, additional, and Okamoto, Isamu, additional

Published
2022
Full Text
View/download PDF

50. A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index

Author

Naito, Tateaki, primary, Uchino, Junji, additional, Kojima, Toru, additional, Matano, Yutaka, additional, Minato, Koichi, additional, Tanaka, Kentaro, additional, Mizukami, Takuro, additional, Atagi, Shinji, additional, Higashiguchi, Takashi, additional, Muro, Kei, additional, Takayama, Koichi, additional, Furuse, Junji, additional, Morishima, Eiichiro, additional, Takiguchi, Toru, additional, and Tamura, Kazuo, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results